Dicerna Pharmaceuticals Company Profile (NASDAQ:DRNA)

About Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals logoDicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DRNA
  • CUSIP: N/A
  • Web: www.dicerna.com
Capitalization:
  • Market Cap: $57.32 million
  • Outstanding Shares: 20,844,000
Average Prices:
  • 50 Day Moving Avg: $3.45
  • 200 Day Moving Avg: $3.13
  • 52 Week Range: $2.42 - $6.10
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $680,000.00
  • Price / Sales: 84.30
  • Book Value: $0.64 per share
  • Price / Book: 4.30
Profitability:
  • EBIDTA: ($57,170,000.00)
  • Net Margins: -8,474.12%
  • Return on Equity: -168.65%
  • Return on Assets: -92.82%
Debt:
  • Current Ratio: 9.57%
  • Quick Ratio: 9.57%
Misc:
  • Average Volume: 108,430 shs.
  • Beta: 2.35
  • Short Ratio: 3.05
 

Frequently Asked Questions for Dicerna Pharmaceuticals (NASDAQ:DRNA)

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($1.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.54. The business earned $0.25 million during the quarter, compared to analysts' expectations of $0.08 million. Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 168.65%. Dicerna Pharmaceuticals's revenue for the quarter was up 2400.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) EPS. View Dicerna Pharmaceuticals' Earnings History.

When will Dicerna Pharmaceuticals make its next earnings announcement?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Dicerna Pharmaceuticals.

Where is Dicerna Pharmaceuticals' stock going? Where will Dicerna Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 1 year price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $4.00 to $13.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $7.25 in the next twelve months. View Analyst Ratings for Dicerna Pharmaceuticals.

What are analysts saying about Dicerna Pharmaceuticals stock?

Here are some recent quotes from research analysts about Dicerna Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (8/22/2017)
  • 2. Cowen and Company analysts commented, "DRNA reported 1Q17 results today." (5/9/2017)

Who are some of Dicerna Pharmaceuticals' key competitors?

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:

  • David M. Madden Ph.D., Independent Chairman of the Board
  • Douglas M. Fambrough Ph.D., President, Chief Executive Officer, Director
  • John B. Green, Chief Financial Officer, Principal Financial Officer
  • Bob D. Brown Ph.D., Senior Vice President, Chief Scientific Officer
  • Theodore T. Ashburn M.D., Ph.D., Senior Vice President - Product Strategy & Operations
  • Pankaj Bhargava M.D., Chief Medical Officer
  • Ralf H. Rosskamp M.D., Chief Medical Officer
  • James B. Weissman, Chief Business Officer
  • Martin I Freed M.D., Independent Director
  • Brian K. Halak Ph.D., Independent Director

Who owns Dicerna Pharmaceuticals stock?

Dicerna Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (11.65%), FMR LLC (11.30%), EcoR1 Capital LLC (3.68%), Palo Alto Investors LLC (2.40%), Vanguard Group Inc. (1.64%) and Omega Fund Management LLC (1.07%). Company insiders that own Dicerna Pharmaceuticals stock include Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

Who sold Dicerna Pharmaceuticals stock? Who is selling Dicerna Pharmaceuticals stock?

Dicerna Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Who bought Dicerna Pharmaceuticals stock? Who is buying Dicerna Pharmaceuticals stock?

Dicerna Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Bourgeon Capital Management LLC, Palo Alto Investors LLC, Vanguard Group Inc. and Northern Trust Corp. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Douglas Fambrough and James B Weissman. View Insider Buying and Selling for Dicerna Pharmaceuticals.

How do I buy Dicerna Pharmaceuticals stock?

Shares of Dicerna Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of Dicerna Pharmaceuticals stock can currently be purchased for approximately $2.75.


MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  215
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $7.25 (163.64% upside)

Analysts' Ratings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017Chardan CapitalReiterated RatingHoldMediumView Rating Details
5/23/2017HC WainwrightReiterated RatingBuy -> Buy$5.00MediumView Rating Details
5/9/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
4/2/2017Jefferies Group LLCReiterated RatingBuy$8.00 -> $7.00LowView Rating Details
2/1/2017Leerink SwannReiterated RatingMkt PerformN/AView Rating Details
9/28/2016Stifel NicolausReiterated RatingBuy$13.00N/AView Rating Details
(Data available from 8/23/2015 forward)

Earnings

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Earnings by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Earnings History by Quarter for Dicerna Pharmaceuticals (NASDAQ DRNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.70)N/AView Earnings Details
8/10/2017Q2 2017($0.61)($1.15)$0.08 million$0.25 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.65)($0.68)$0.08 million$0.13 millionViewListenView Earnings Details
3/30/2017Q4 2016($0.73)($0.68)$0.13 millionViewN/AView Earnings Details
11/7/2016Q316($0.87)($0.68)$162.00 millionViewListenView Earnings Details
8/4/2016Q216($0.84)($0.75)ViewN/AView Earnings Details
5/9/2016Q116($0.86)($0.76)ViewN/AView Earnings Details
3/10/2016Q415($0.84)($0.76)$2.50 millionViewListenView Earnings Details
11/10/2015Q315($0.84)($0.82)ViewListenView Earnings Details
8/6/2015Q215($0.78)($0.86)$0.18 millionViewN/AView Earnings Details
5/11/2015Q1($0.73)($0.79)$600.00 millionViewListenView Earnings Details
3/12/2015Q414($0.57)($0.63)$1.45 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.63)($0.63)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.42)($0.64)ViewN/AView Earnings Details
5/13/2014Q114($0.52)($0.76)ViewN/AView Earnings Details
3/27/2014($0.62)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)
2017 EPS Consensus Estimate: ($2.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.73)($0.59)($0.66)
Q2 20172($0.73)($0.68)($0.71)
Q3 20172($0.67)($0.50)($0.59)
Q4 20172($0.66)($0.50)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Insider Ownership Percentage: 29.41%
Institutional Ownership Percentage: 56.05%
Insider Trades by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Insider Trades by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2016Dennis LangerDirectorSell23,766$3.52$83,656.32View SEC Filing  
11/15/2016Douglas FambroughCEOBuy33,100$3.71$122,801.00View SEC Filing  
5/12/2016James B WeissmanInsiderBuy5,000$3.29$16,450.00View SEC Filing  
11/25/2014James E FlynnInsiderSell321,965$11.36$3,657,522.40View SEC Filing  
11/7/2014James E FlynnInsiderSell214,164$9.05$1,938,184.20View SEC Filing  
10/15/2014James E FlynnInsiderSell117,778$10.86$1,279,069.08View SEC Filing  
10/14/2014James E FlynnMajor ShareholderSell36,115$11.02$397,987.30View SEC Filing  
10/10/2014James E FlynnMajor ShareholderSell30,214$12.13$366,495.82View SEC Filing  
2/4/2014James E FlynnInsiderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
2/4/2014Stephen J HoffmanDirectorBuy200,000$15.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Latest Headlines for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Source:
DateHeadline
americanbankingnews.com logoDicerna Pharmaceuticals, Inc. (DRNA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - August 22 at 9:26 PM
americanbankingnews.com logoDicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 15 at 6:32 PM
americanbankingnews.com logoDicerna Pharmaceuticals, Inc. (DRNA) Given "Hold" Rating at Chardan Capital
www.americanbankingnews.com - August 14 at 8:36 AM
finance.yahoo.com logoEdited Transcript of DRNA earnings conference call or presentation 10-Aug-17 8:30pm GMT
finance.yahoo.com - August 11 at 5:23 AM
americanbankingnews.com logoDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Releases Earnings Results, Misses Expectations By $0.47 EPS
www.americanbankingnews.com - August 10 at 10:42 PM
finance.yahoo.com logoDicerna Reports Second Quarter 2017 Financial and Operating Results and Provides Corporate Update
finance.yahoo.com - August 10 at 7:16 PM
finance.yahoo.com logoDicerna Pharmaceuticals posts 2Q loss
finance.yahoo.com - August 10 at 7:16 PM
finance.yahoo.com logoDicerna to Report Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
finance.yahoo.com - August 3 at 5:06 PM
americanbankingnews.com logoDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 24 at 8:28 PM
americanbankingnews.com logoDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - July 22 at 9:04 AM
americanbankingnews.com logoDicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 6:51 PM
americanbankingnews.com logoZacks Investment Research Downgrades Dicerna Pharmaceuticals, Inc. (DRNA) to Sell
www.americanbankingnews.com - July 18 at 10:20 PM
finance.yahoo.com logoDicerna Expands Lead GalXC™ Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC
finance.yahoo.com - July 17 at 11:28 AM
americanbankingnews.com logoDicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 26 at 6:49 PM
seekingalpha.com logoDicerna Pharmaceuticals (DRNA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 5:44 PM
finance.yahoo.com logoDicerna to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 5:29 PM
247wallst.com logo7 Speculative Biotech and Pharma Stocks That Could Still Double (or More)
247wallst.com - May 31 at 9:41 AM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 30 at 4:48 PM
reuters.com logoBain Capital raises $720 million for life sciences fund
www.reuters.com - May 23 at 12:24 PM
finance.yahoo.com logo​Bain Capital rakes in $720M for first life sciences fund
finance.yahoo.com - May 23 at 12:24 PM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - May 23 at 7:36 AM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 16 at 8:18 PM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) to Post Q2 2017 Earnings of ($0.68) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 11 at 8:52 AM
americanbankingnews.com logoCowen and Company Reiterates Buy Rating for Dicerna Pharmaceuticals Inc (DRNA)
www.americanbankingnews.com - May 9 at 10:28 PM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Announces Earnings Results
www.americanbankingnews.com - May 9 at 1:56 PM
finance.yahoo.com logoDicerna Pharmaceuticals posts 1Q loss
finance.yahoo.com - May 9 at 6:44 AM
finance.yahoo.com logoEdited Transcript of DRNA earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 9 at 6:44 AM
finance.yahoo.com logoInvestor Network: Dicerna Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 4:41 PM
finance.yahoo.com logoDicerna Reports First Quarter 2017 Financial and Operational Results and Provides Corporate Update
finance.yahoo.com - May 8 at 4:41 PM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 5 at 10:52 AM
americanbankingnews.com logoDicerna Pharmaceuticals (DRNA) Receiving Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 6:32 PM
americanbankingnews.com logoDicerna Pharmaceuticals (DRNA) Earning Somewhat Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 1 at 6:04 PM
finance.yahoo.com logoDicerna to Report First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017
finance.yahoo.com - May 1 at 4:39 PM
americanbankingnews.com logoSomewhat Positive News Coverage Unlikely to Affect Dicerna Pharmaceuticals (DRNA) Share Price
www.americanbankingnews.com - April 28 at 5:45 PM
americanbankingnews.com logoDicerna Pharmaceuticals (DRNA) Receiving Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 25 at 6:00 PM
americanbankingnews.com logoDicerna Pharmaceuticals (DRNA) Earning Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 20 at 10:09 PM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 17 at 7:52 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Effect Dicerna Pharmaceuticals (DRNA) Stock Price
www.americanbankingnews.com - April 16 at 1:50 PM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Price Target Lowered to $5.00 at HC Wainwright
www.americanbankingnews.com - April 14 at 7:12 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Likely to Effect Dicerna Pharmaceuticals (DRNA) Share Price
www.americanbankingnews.com - April 13 at 6:15 PM
finance.yahoo.com logoDicerna Announces Closing of $70 Million Convertible Preferred Stock Financing
finance.yahoo.com - April 12 at 9:35 AM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 11 at 10:18 PM
seekingalpha.com logoDicerna Pharmaceuticals (DRNA) Presents At The 24th Annual Future Leaders in the Biotech Industry Conference - Slideshow
seekingalpha.com - April 11 at 12:48 PM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 10 at 11:51 AM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Price Target Cut to $5.00 by Analysts at HC Wainwright
www.americanbankingnews.com - April 10 at 8:47 AM
americanbankingnews.com logoJefferies Group LLC Reiterates "Buy" Rating for Dicerna Pharmaceuticals Inc (DRNA)
www.americanbankingnews.com - April 9 at 10:32 AM
finance.yahoo.com logoDicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: 2016 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 9:27 AM
finance.yahoo.com logoETFs with exposure to Dicerna Pharmaceuticals, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:27 AM
americanbankingnews.com logoJefferies Group Weighs in on Dicerna Pharmaceuticals Inc's FY2021 Earnings (DRNA)
www.americanbankingnews.com - April 3 at 1:02 PM
americanbankingnews.com logoDicerna Pharmaceuticals Inc (DRNA) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 2 at 10:31 PM

Social

Chart

Dicerna Pharmaceuticals (DRNA) Chart for Wednesday, August, 23, 2017

This page was last updated on 8/23/2017 by MarketBeat.com Staff